HCPLive Network

Exposure to Tamoxifen Causes CNS Cell Death

 
THURSDAY, Sept. 19 (HealthDay News) -- Tamoxifen causes central nerve system (CNS) cell cytotoxicity, and MEK1/2 inhibition can prevent tamoxifen-induced cell death, according to a study published in the Sept. 18 issue of The Journal of Neuroscience.

Hsing-Yu Chen, from the University of Rochester Medical School in New York, and colleagues examined the impact of exposure to tamoxifen on CNS cell populations.

The researchers found that, in vitro, tamoxifen was cytotoxic for various CNS cell populations, and it was associated with increased cell death in the corpus callosum. In addition, tamoxifen was associated with reduced cell division in the mouse subventricular zone, the hippocampal dentate gyrus, and the corpus callosum. In vitro, MEK1/2 inhibition selectively rescued primary glial progenitors from tamoxifen cytotoxicity, while simultaneously enhancing the effect of tamoxifen on MCF7 luminal human breast cancer cells. In systematically treated mice, in vivo MEK1/2 inhibition prevented tamoxifen-induced cell death.

"Our results demonstrate unexpected cytotoxicity of this putatively benign anti-hormonal agent and offer a potential strategy for rescuing CNS cells from adverse effects of tamoxifen," the authors write.

Abstract 

Full Text (subscription or payment may be required) 

Copyright © 2013 HealthDay. All rights reserved.
 
 
 

Further Reading
Extending the duration of adjuvant tamoxifen treatment to 10 years was more effective than the standard 5 years of treatment in protecting against recurrence and death among women with ER+ breast cancer.
The increased risk of breast cancer among users of hormone replacement therapy varies by race/ethnicity, body mass index, and breast density, according to a study published online Sept. 3 in the Journal of the National Cancer Institute.
In cell culture and mice studies, bazedoxifene inhibited estrogen-induced gene expression and cell proliferation in cancer cells, including those that were tamoxifen-resistant.
Multiple studies presented at the San Antonio Breast Cancer Symposium report encouraging findings on the role of aromatase inhibitors in treating postmenopausal women with early-stage estrogen receptor-positive breast cancer.
Multiple studies presented at the San Antonio Breast Cancer Symposium report encouraging findings on the role of aromatase inhibitors in treating postmenopausal women with early-stage estrogen receptor-positive breast cancer.
Tamoxifen, long considered the gold standard for treating estrogen-receptor (ER) positive, early-stage breast cancer, is known to increase the risk of thrombotic events (blood clots).
Giving tamoxifen for 2 years followed by 3 years of anastrozole (sequencing strategy) improved relapse-free survival and overall survival compared to 5 years of tamoxifen in postmenopausal women with newly diagnosed, hormone-sensitive, early breast cancer.
More Reading